The hereditary forms of breast cancer identified by BRCA1 and BRCA2 genes have a defect
in homologous DNA repair and demonstrate a dependence on alternate DNA repair …

PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage. PARP
inhibitors have been under development since 1980 and first entered clinical trial in 2003 …

Inhibition of the DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP-1) has been
extensively investigated in the pre-clinical setting as a strategy for chemo-or radio …

A number of inhibitors of DNA repair have been evaluated or are undergoing development
as potential cancer treatments. Inhibitors of poly (ADP-ribose) polymerase (PARP) are of …

Poly (ADP-Ribose) Polymerase (PARP) is a family of enzymes involved in DNA repair,
genome stability, cellular energy metabolism and cell division. Inhibition of PARP-1, the …

PARP [poly (ADP-ribose) polymerase] activity is up-regulated by binding to DNA strand
breaks and its association with DNA repair is well documented. Many anticancer therapies …

Background Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, with
novel and selective mechanisms of action, have moved from the laboratory to the clinic in …

Abstract Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals the
presence of DNA damage by catalyzing the addition of ADP-ribose units to DNA, histones …

Inbuilt mechanisms of DNA surveillance and repair are integral to the maintenance of
genomic stability. Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that plays a …

PARP-1 [poly (ADP-ribose) polymerase-1], which plays a key role in DNA repair, was
discovered 50 years ago. PARPi (PARP inhibitors), originally made to probe the function of …